India CDMO Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Country: (India)
Description
India’s Contract Development and Manufacturing Organization (CDMO) market is experiencing rapid transformation, solidifying the country’s position as a global pharmaceutical outsourcing hub. Fueled by its cost-competitive manufacturing Analysis, robust infrastructure, and skilled scientific workforce, India has become an attractive destination for global pharmaceutical companies seeking end-to-end development and manufacturing services. With a growing focus on generics, biosimilars, and biologics, India’s CDMO industry is poised for significant growth in the years ahead.
Market Overview
The India CDMO market is projected to expand at a CAGR of 12.06% between 2025 and 2032. The market is anticipated to increase from US$ 26.75 Bn in 2025 to reach US$ 59.35 Bn by 2032. This growth is supported by India’s strong reputation for producing high-quality, affordable medicines and its alignment with international regulatory standards. The combination of technical know-how, large-scale production capabilities, and favorable government initiatives continues to drive interest and investments into the sector.
Market Growth Drivers
A key factor fueling growth is India’s cost-efficiency in pharmaceutical manufacturing. The country offers one of the lowest cost bases globally without compromising on quality or regulatory compliance. Indian CDMOs benefit from a mature infrastructure, large pool of scientific talent, and proven expertise in Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), particularly for small molecule drugs.
The expiry of patents on several blockbuster drugs is also increasing global demand for generics and biosimilars. India, as a leading producer of generics, is well-positioned to meet this demand. CDMOs in India are also expanding capabilities in biologics, an area of rising interest due to the global shift toward advanced therapies.
Emerging Opportunities
One of the most promising opportunities for Indian CDMOs is the rising global trend of outsourcing drug development and manufacturing. Pharmaceutical companies are increasingly focusing on core competencies such as R&D and commercialization while outsourcing production to lower-cost, high-quality service providers. India, with its end-to-end capabilities—from preclinical studies to commercial manufacturing—has become a top choice for such partnerships.
Moreover, the development of biosimilars, vaccines, and biologics presents a new growth frontier. Several Indian CDMOs are making strategic investments in biologics manufacturing, bioprocessing technologies, and viral vector production to serve this growing market.
Regional Strengths
India’s CDMO market is strongly supported by well-established pharmaceutical hubs such as Hyderabad, Mumbai, Ahmedabad, and Bengaluru. Hyderabad, home to Genome Valley, has emerged as a biotech hub, while Bengaluru leads in contract research and formulation development. Mumbai and Ahmedabad remain key centers for API and FDF production.
These cities offer access to modern infrastructure, talent, and government-backed incentives, enabling India to efficiently cater to global pharmaceutical demands. The regional ecosystems are further strengthened by proximity to ports, logistics hubs, and international regulatory support.
Competitive Analysis
India’s CDMO Analysis is dynamic and competitive, with leading players including:
• Piramal Pharma Solutions
• Syngene International
• Dr. Reddy’s Laboratories
• Divi’s Laboratories
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Jubilant Pharmova
• Glenmark Pharmaceuticals
• Capsule Pharma
• Laurus Labs
• Strides Pharma Science
• Aurigene Pharmaceutical
These companies have established themselves as global partners by offering quality manufacturing, scalable operations, and regulatory expertise. While large players dominate small molecule and generic production, many are now investing in biologics and high-value therapies to diversify their portfolios. Partnerships, mergers, and strategic expansions are common as players seek to strengthen global presence and technological capabilities.
Recent Industry Developments
In June 2024, Lupin announced its entry into the CDMO sector with the launch of Lupin Manufacturing Solutions (LMS). This strategic expansion into contract services signifies Lupin’s focus on leveraging India’s strengths in manufacturing. Abdelaziz Toumi was appointed as CEO to lead the initiative.
In May 2023, Aurigene Pharmaceutical Services, part of Dr. Reddy’s Laboratories, committed US$ 40 million to build a cutting-edge facility in Genome Valley, Hyderabad. This facility will focus on therapeutic proteins, antibodies, and viral vectors and is expected to become operational by the first half of 2024, boosting India’s biologics manufacturing capacity.
Market Restraints
Despite its advantages, India faces challenges that could impact growth in the CDMO market. One of the primary concerns is the gap in infrastructure and technological readiness for biologics and advanced therapeutics. While India leads in small molecule production, it still lags in high-end manufacturing technologies required for cell and gene therapies, monoclonal antibodies, and other complex biologics.
Significant investment is needed to modernize existing facilities and develop capabilities in these emerging segments. Limited expertise in cutting-edge biologic platforms and the need for specialized talent also present obstacles that companies must address to maintain competitiveness.
Future Outlook
India’s CDMO market is on a strong upward trajectory, driven by global outsourcing trends, demand for cost-effective therapeutics, and the country’s manufacturing excellence. Continued government support, industry collaboration, and investment in innovation will be crucial for the sector to expand further into high-margin areas like biologics and personalized medicine.
As pharmaceutical companies globally prioritize flexibility, speed-to-market, and reduced overheads, India’s role as a reliable outsourcing partner is expected to become even more prominent.
India CDMO Market Segmentation
By Service Type
• Contract Development Services
o Preclinical Development
o Clinical Development
o Analytical and Bioanalytical Services
• Contract Manufacturing Services
o Active Pharmaceutical Ingredients (APIs) Manufacturing
o Finished Dosage Forms (FDFs) Manufacturing
o Biologics Manufacturing
o Packaging
By Product Type
• Small Molecules
• Biologics
• Biosimilars
• Vaccines
• Others
By Scale of Operation
• Commercial Scale
• Clinical Scale
By Therapeutic Area
• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Central Nervous System (CNS) Disorders
• Others
Please note: Delivery Timeline - 5 working days.
Market Overview
The India CDMO market is projected to expand at a CAGR of 12.06% between 2025 and 2032. The market is anticipated to increase from US$ 26.75 Bn in 2025 to reach US$ 59.35 Bn by 2032. This growth is supported by India’s strong reputation for producing high-quality, affordable medicines and its alignment with international regulatory standards. The combination of technical know-how, large-scale production capabilities, and favorable government initiatives continues to drive interest and investments into the sector.
Market Growth Drivers
A key factor fueling growth is India’s cost-efficiency in pharmaceutical manufacturing. The country offers one of the lowest cost bases globally without compromising on quality or regulatory compliance. Indian CDMOs benefit from a mature infrastructure, large pool of scientific talent, and proven expertise in Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), particularly for small molecule drugs.
The expiry of patents on several blockbuster drugs is also increasing global demand for generics and biosimilars. India, as a leading producer of generics, is well-positioned to meet this demand. CDMOs in India are also expanding capabilities in biologics, an area of rising interest due to the global shift toward advanced therapies.
Emerging Opportunities
One of the most promising opportunities for Indian CDMOs is the rising global trend of outsourcing drug development and manufacturing. Pharmaceutical companies are increasingly focusing on core competencies such as R&D and commercialization while outsourcing production to lower-cost, high-quality service providers. India, with its end-to-end capabilities—from preclinical studies to commercial manufacturing—has become a top choice for such partnerships.
Moreover, the development of biosimilars, vaccines, and biologics presents a new growth frontier. Several Indian CDMOs are making strategic investments in biologics manufacturing, bioprocessing technologies, and viral vector production to serve this growing market.
Regional Strengths
India’s CDMO market is strongly supported by well-established pharmaceutical hubs such as Hyderabad, Mumbai, Ahmedabad, and Bengaluru. Hyderabad, home to Genome Valley, has emerged as a biotech hub, while Bengaluru leads in contract research and formulation development. Mumbai and Ahmedabad remain key centers for API and FDF production.
These cities offer access to modern infrastructure, talent, and government-backed incentives, enabling India to efficiently cater to global pharmaceutical demands. The regional ecosystems are further strengthened by proximity to ports, logistics hubs, and international regulatory support.
Competitive Analysis
India’s CDMO Analysis is dynamic and competitive, with leading players including:
• Piramal Pharma Solutions
• Syngene International
• Dr. Reddy’s Laboratories
• Divi’s Laboratories
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Jubilant Pharmova
• Glenmark Pharmaceuticals
• Capsule Pharma
• Laurus Labs
• Strides Pharma Science
• Aurigene Pharmaceutical
These companies have established themselves as global partners by offering quality manufacturing, scalable operations, and regulatory expertise. While large players dominate small molecule and generic production, many are now investing in biologics and high-value therapies to diversify their portfolios. Partnerships, mergers, and strategic expansions are common as players seek to strengthen global presence and technological capabilities.
Recent Industry Developments
In June 2024, Lupin announced its entry into the CDMO sector with the launch of Lupin Manufacturing Solutions (LMS). This strategic expansion into contract services signifies Lupin’s focus on leveraging India’s strengths in manufacturing. Abdelaziz Toumi was appointed as CEO to lead the initiative.
In May 2023, Aurigene Pharmaceutical Services, part of Dr. Reddy’s Laboratories, committed US$ 40 million to build a cutting-edge facility in Genome Valley, Hyderabad. This facility will focus on therapeutic proteins, antibodies, and viral vectors and is expected to become operational by the first half of 2024, boosting India’s biologics manufacturing capacity.
Market Restraints
Despite its advantages, India faces challenges that could impact growth in the CDMO market. One of the primary concerns is the gap in infrastructure and technological readiness for biologics and advanced therapeutics. While India leads in small molecule production, it still lags in high-end manufacturing technologies required for cell and gene therapies, monoclonal antibodies, and other complex biologics.
Significant investment is needed to modernize existing facilities and develop capabilities in these emerging segments. Limited expertise in cutting-edge biologic platforms and the need for specialized talent also present obstacles that companies must address to maintain competitiveness.
Future Outlook
India’s CDMO market is on a strong upward trajectory, driven by global outsourcing trends, demand for cost-effective therapeutics, and the country’s manufacturing excellence. Continued government support, industry collaboration, and investment in innovation will be crucial for the sector to expand further into high-margin areas like biologics and personalized medicine.
As pharmaceutical companies globally prioritize flexibility, speed-to-market, and reduced overheads, India’s role as a reliable outsourcing partner is expected to become even more prominent.
India CDMO Market Segmentation
By Service Type
• Contract Development Services
o Preclinical Development
o Clinical Development
o Analytical and Bioanalytical Services
• Contract Manufacturing Services
o Active Pharmaceutical Ingredients (APIs) Manufacturing
o Finished Dosage Forms (FDFs) Manufacturing
o Biologics Manufacturing
o Packaging
By Product Type
• Small Molecules
• Biologics
• Biosimilars
• Vaccines
• Others
By Scale of Operation
• Commercial Scale
• Clinical Scale
By Therapeutic Area
• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Central Nervous System (CNS) Disorders
• Others
Please note: Delivery Timeline - 5 working days.
Table of Contents
148 Pages
- 1. Executive Summary
- 1.1. India CDMO Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value, 2025
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. India CDMO Market Outlook, 2019-2032
- 3.1. India CDMO Market Outlook, by Service Type, Value (US$ Bn), 2019-2032
- 3.1.1. Key Highlights
- 3.1.1.1. Contract Development Services
- 3.1.1.1.1. Preclinical Development
- 3.1.1.1.2. Clinical Development
- 3.1.1.1.3. Analytical and Bioanalytical Services
- 3.1.1.2. Contract Manufacturing Services
- 3.1.1.2.1. Active Pharmaceutical Ingredients (APIs) Manufacturing
- 3.1.1.2.2. Finished Dosage Forms (FDFs) Manufacturing
- 3.1.1.2.3. Biologics Manufacturing
- 3.1.1.2.4. Packaging
- 3.2. India CDMO Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
- 3.2.1. Key Highlights
- 3.2.1.1. Small Molecules
- 3.2.1.2. Biologics
- 3.2.1.3. Biosimilars
- 3.2.1.4. Vaccines
- 3.2.1.5. Others
- 3.3. India CDMO Market Outlook, by Scale of Operation, Value (US$ Bn), 2019-2032
- 3.3.1. Key Highlights
- 3.3.1.1. Commercial Scale
- 3.3.1.2. Clinical Scale
- 3.4. India CDMO Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
- 3.4.1. Key Highlights
- 3.4.1.1. Oncology
- 3.4.1.2. Cardiovascular Diseases
- 3.4.1.3. Infectious Diseases
- 3.4.1.4. Central Nervous System (CNS) Disorders
- 3.4.1.5. Others
- 4. Competitive Landscape
- 4.1. Company Market Share Analysis, 2025
- 4.2. Competitive Dashboard
- 4.3. Company Profiles
- 4.3.1. Piramal Pharma Solutions
- 4.3.1.1. Company Overview
- 4.3.1.2. Service Type Portfolio
- 4.3.1.3. Financial Overview
- 4.3.1.4. Business Strategies and Development
- 4.3.2. Syngene International
- 4.3.2.1. Company Overview
- 4.3.2.2. Service Type Portfolio
- 4.3.2.3. Financial Overview
- 4.3.2.4. Business Strategies and Development
- 4.3.3. Dr. Reddy’s Laboratories
- 4.3.3.1. Company Overview
- 4.3.3.2. Service Type Portfolio
- 4.3.3.3. Financial Overview
- 4.3.3.4. Business Strategies and Development
- 4.3.4. Divi’s Laboratories
- 4.3.4.1. Company Overview
- 4.3.4.2. Service Type Portfolio
- 4.3.4.3. Financial Overview
- 4.3.4.4. Business Strategies and Development
- 4.3.5. Lupin Limited
- 4.3.5.1. Company Overview
- 4.3.5.2. Service Type Portfolio
- 4.3.5.3. Financial Overview
- 4.3.5.4. Business Strategies and Development
- 4.3.6. Sun Pharmaceutical Industries Ltd.
- 4.3.6.1. Company Overview
- 4.3.6.2. Service Type Portfolio
- 4.3.6.3. Financial Overview
- 4.3.6.4. Business Strategies and Development
- 4.3.7. Aurobindo Pharma
- 4.3.7.1. Company Overview
- 4.3.7.2. Service Type Portfolio
- 4.3.7.3. Financial Overview
- 4.3.7.4. Business Strategies and Development
- 4.3.8. Jubilant Pharmova (Jubilant Biosys & Jubilant Generics)
- 4.3.8.1. Company Overview
- 4.3.8.2. Service Type Portfolio
- 4.3.8.3. Financial Overview
- 4.3.8.4. Business Strategies and Development
- 4.3.9. Glenmark Pharmaceuticals
- 4.3.9.1. Company Overview
- 4.3.9.2. Service Type Portfolio
- 4.3.9.3. Financial Overview
- 4.3.9.4. Business Strategies and Development
- 4.3.10. Capsule Pharma
- 4.3.10.1. Company Overview
- 4.3.10.2. Service Type Portfolio
- 4.3.10.3. Financial Overview
- 4.3.10.4. Business Strategies and Development
- 4.3.11. Laurus Labs
- 4.3.11.1. Company Overview
- 4.3.11.2. Service Type Portfolio
- 4.3.11.3. Financial Overview
- 4.3.11.4. Business Strategies and Development
- 4.3.12. Strides Pharma Science
- 4.3.12.1. Company Overview
- 4.3.12.2. Service Type Portfolio
- 4.3.12.3. Financial Overview
- 4.3.12.4. Business Strategies and Development
- 4.3.13. Aurigene Pharmaceutical
- 4.3.13.1. Company Overview
- 4.3.13.2. Service Type Portfolio
- 4.3.13.3. Financial Overview
- 4.3.13.4. Business Strategies and Development
- 4.3.14. Others
- 4.3.14.1. Company Overview
- 4.3.14.2. Service Type Portfolio
- 4.3.14.3. Financial Overview
- 4.3.14.4. Business Strategies and Development
- 5. Appendix
- 5.1. Research Methodology
- 5.2. Report Assumptions
- 5.3. Acronyms and Abbreviations
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
